Ensuring Efficient Drug Delivery: Akums' Quality Evaluation of Nanoparticles
The majority of the medications fall into Biopharmaceutics Classification System (BCS) class II, where low solubility is the rate-limiting step for penetration, nanoparticles are used to improve solubility. Analyzing physicochemical characteristics using suitable analytical techniques is crucial to ensure their efficiency, formulation process repeatability, functional performance, and system stability.
Nanoparticles improve drug delivery systems by enhancing solubility, bioavailability, and targeting. Analytical approaches aid in understanding their shape, size, and surface characteristics, allowing for tailored drug delivery to specific tissues or cells, and improving therapeutic efficiency while reducing adverse effects.
In the area of nanoparticle analysis, Akums employs advanced analytical techniques, including high-performance liquid chromatography (HPLC), Atomic Absorption Spectrometer, and scanning electron microscopy (SEM), which adhere to global standards. These methods are used to characterize and analyze the physicochemical properties of nanoparticle-based drugs, ensuring that they meet the highest standards of quality and effectiveness.
It is important to analyze the chemical-physiological characteristics of nanoparticles because these characteristics can affect how the nanoparticles interact with biological systems and impact their efficacy and safety. Understanding the size, shape, surface charge, and other properties of drug nanoparticles can help to optimize their design and ensure that they can be administered safely and effectively.
The quality and analysis of nanosystems are much more challenging than those of bulk materials or microparticle systems. At the nanoscale, several physical parameters differ from their bulk counterparts. Nanoparticles are inherently unstable and tend to aggregate and when drug nanoparticles encounter bodily fluids, they tend to disintegrate quickly. In nanoparticle formulations, it is crucial to analyze desirable particle characteristics and their critical quality attributes (CQAs) to identify whether the particles should be engineered to dissolve instantly or whether the aim is controlled drug release from solid particles.
Understanding drug release is crucial in developing targeted delivery systems. High-performance liquid chromatography (HPLC) is commonly used to assess the stability and purity of nanoparticles. It quantifies degradation products and impurities and detects chemical changes during storage and use. It’s commonly used to analyze nanoparticle drug stability under varying conditions, as well as to measure their concentration over time. Moreover, it separates and quantifies components, ensuring nanoparticle purity and meeting regulatory standards. Overall, HPLC is a powerful technique in pharmaceuticals for developing and ensuring the quality of nanoparticles.
Akums possesses a considerable collection of more than 400 HPLC machines that are solely dedicated to the analysis of their drug formulations. These HPLC machines are high-tech instruments utilized for performing precise and accurate analyses of drugs to verify their quality, potency, and purity.
Electron microscopy techniques like SEM are crucial for managing the physical and chemical characteristics of nanoparticles. They provide information on particle size, structure, and morphology, and aid in developing effective drug delivery systems. SEM’s unique imaging and detection capabilities allow for the analysis of structural morphology at the atomic or molecular level.
Nanoparticle characterization involves various analytical techniques, such as IR and Raman spectroscopy, light scattering-based techniques, and zeta potential. IR and Raman’s spectroscopy reveal the chemical composition and functional groups and crystalline structure.
Akums recognizes the enormous potential of nanoparticles in targeted delivery to specific tissues or cells. However, to harness these benefits, it’s crucial to have a deep understanding of the morphology, size, and surface properties of nanoparticles. This information is essential for the development of effective and efficient drug delivery systems. Our scientists at research labs continuously endeavor to research on nano-technology to improve the quality of medicines.
Satwinder Singh is an Independent Director of our Company. He holds a bachelor’s degree in commerce and a bachelor’s degree in law from Guru Nanak Dev University, Punjab. He is a fellow member of the Institute of Company Secretaries of India (‘ICSI’).
He was the past Chairman of Expert Group on Secretarial Standards and Secretarial Standards Committee for the years 2021 and 2022. He has also held the chairmanship of the Secretarial Standards Board for the years 2019 and 2020. He was also the Chairman of the Task Force on NCLT/NCLAT for the year 2023.
Sanjay Sinha is a Whole Time Director of our Company. He holds a bachelor’s degree in pharmaceutical sciences from Ranchi University and a master’s degree in pharmacy from the University of Delhi. He was previously associated with Ipca Laboratories Limited and Famy Care Limited.
He joined our Company with effect from November 26, 2022 as President of Operations.
Ms. Gowrishankar comes with a wide range of experience across different domains.
Besides Akums, she is currently an independent director on the boards of several prominent companies including Cyient, Gabriel India, Greenlam Industries, Arohan Financial Services, Ashv Finance, Intellecap Advisory Services, Altum Credo Home Finance and Premium Transmission.
In the past, Ms. Gowrishankar has served on the boards of BP India Services, the holding company of oil and gas major BP in India, and subsidiaries of Cummins India.
Not only has she led teams both in India and outside, she has also been an executive coach to the top leadership at BP plc and other companies.
Ms. Gowrishankar has been a strategic human resources advisor to companies like Safari Industries, FlyNava Technologies, Quantum Consumer Solutions, BP Global Solutions India and Cornerstone India, to name a few. She was also heading the group HR council for the Aavishkaar Group.
She holds a postgraduate degree in personnel management and industrial relations from the prestigious XLRI, Jamshedpur, and a bachelor of arts in sociology from Stella Maris College, Chennai.
A former career bureaucrat, Mr. Kalra spent 36 years in the elite Indian Revenue Service (IRS), and held various important positions. He now heads the audit committee of the company, as its chairman.
From 2005-12, Mr. Kalra was a member of the Income Tax Appellate Tribunal, where he delivered several landmark judgements. Before that, Mr. Kalra served as the assistant commissioner, deputy commissioner, joint commissioner and additional commissioner in the income tax department and has served across the country.
Mr. Kalra, who has worked actively to extend financial help to underprivileged children, has an excellent academic record. He earned a Bachelor of Science degree from Kurukshetra University with a gold medal. He holds a masters in science from Panjab University and a law degree from Jodhpur University.
Mr. Handa is a veteran of the pharmaceutical industry in India. He headed Pfizer India as managing director and country manager from 2005 to 2012. Before Pfizer, he was also the managing director at Wyeth Ltd.
After leaving Pfizer, Mr Handa joined Samarth Life Sciences as President. He went on to serve as the non-executive chairman on the board of Union Bank of India, one of the most prominent government-owned lenders. Mr. Handa recently also joined the board of merchant payments firm BharatPe as an independent director.
Mr. Handa has diverse experience in finance, commercial, strategy, business development, M&A, banking, corporate affairs. He is also experienced across sectors like engineering and consumer in companies
like Schrader Scovill, Hindustan Unilever Limited, and State Industrial Investment Corporation of Maharashtra. Mr. Handa has wide experience in markets like the US, Southeast Asia, Africa, Bangladesh, and Sri Lanka.
One of Mr. Handa’s key focus areas is building a diverse organisation. He has driven various teams to hire and retain women colleagues in management and most importantly in sales positions – an initiative unheard of in the Indian pharmaceutical industry. He has managed this by sensitization and by developing women-friendly policies. These initiatives are now case studies and were showcased at a ministerial roundtable held in Turkey.
Mr. Handa is a qualified management accountant and company secretary, and has a master’s degree in commerce
Sunil Kumar Thakur is a Non-Executive Director of our Company and is a nominee of Ruby QC Investment Holdings Pte. Ltd. on our Board. He holds a bachelor’s degree in business administration from Thames Valley University and a master’s degree in international business from the University of Delhi.
He is currently associated with Quadria Capital Advisors Private Limited as a partner, where he leads the investments, portfolio management and divestment activities across South-Asia and also serves on the investment committee of the Quadria Capital Fund II GP.
Mr. Rathore is a three-decade old veteran of the pharmaceutical industry. He is an accomplished, outcome-driven executive with a proven track record in leading challenging initiatives, with emphasis on strategic planning, manufacturing, engineering, quality assurance, project development, budget management and human resources.
Mr. Rathore has, over the years, shown tremendous leadership ability and has extensive experience in managing pharmaceutical plants as per international standards.
Mr. Rathore holds a master’s degree in pharmacy and a postgraduate diploma in management from Rajasthan University.Before Akums, Mr. Rathore worked with companies like Bal Pharma, Tirupati Zion Medicare, Micro Labs, Scott-Edil Pharmacia, Nicholas Piramal, Lupin and Torrent Pharma.
Mr. Sandeep Jain has been the force behind setting up Akums’ state-of-the-art world-class facilities. He has had a key role in making contract manufacturing the most viable industry model.
He has been associated with several leading trade and industry bodies and has advocated the cause of the Indian pharmaceutical sector. In 2013-14, he was the president of the Uttarakhand state council of the Confederation of Indian Industry (CII). The same year, he also headed the state’s Association of Pharmaceutical
He has also served as the chairman of the Chamber of Commerce and Industry, Uttarakhand and has been a member of the managing committee of the PHD Chamber of Commerce and Industry and the vice-chairman of the Foundation of Pharma Entrepreneurs (FOPE)
Mr. Sanjeev Jain was the principal force behind founding Akums, and ranks among the pioneers of the Indian pharma sector. Mr. Jain is known as a visionary leader and mentor. He has been guiding not just Akums but the industry as a whole to greater heights over the last decade and a half.
A people person, he has more than three decades of experience in the field of pharmaceuticals sales and marketing. He has received multiple industry awards, including the prestigious Dynamic Entrepreneur Award at the 6th Annual Pharmaceutical Leadership Summit & Business Leadership Awards in 2014.
Under his leadership, Akums has made several national and foreign collaborations. His innovative ideas in product development, patents, and customer retention have helped the company chart new growth paths over the year